WHO Drug Information Vol. 18, No. 1, 2004
(2004; 109 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory Challenges
Abrir esta carpeta y ver su contenidoEssential Medicines
Abrir esta carpeta y ver su contenidoSafety and Efficacy Issues
Abrir esta carpeta y ver su contenidoVaccines and Biomedicines
Abrir esta carpeta y ver su contenidoHerbal Medicines
Cerrar esta carpetaRegulatory and Safety Action
Ver el documentoNevirapine and hepatotoxicity
Ver el documentoAntidepressants in adults and children
Ver el documentoRecommended influenza vaccines: 2004-2005
Ver el documentoOlanzapine and cerebrovascular events
Ver el documentoOlanzapine: hyperglycaemia and diabetes
Ver el documentoBetter labelling for ingredient sensitivities
Abrir esta carpeta y ver su contenidoConsultation Document
Ver el documentoProposed International Nonproprietary Names: List 90
Ver el documentoRecommended International Nonproprietary Names: List 51
 

Recommended influenza vaccines: 2004-2005

World Health Organization - The composition of influenza vaccines for the Northern hemisphere 2004-2005 Winter season has been determined as follows:

• an A/New Caledonia/20/99(H1N1)-like virus

• an A/Fjian/411/2002(H3N2)-like virus. (The currently used vaccine virus is A/Wyoming/3/ 2003 A/Kumamoto/102/2002 is also available.)

• a B/Shanghai/361/2002-like virus. (Candidate vaccine viruses include B/Shanghai/361/2002 and B/Jilin/20/2003.)


The national control authorities should approve the specific vaccine viruses used in each country. National public health authorities are responsible for recommendations regarding use of the vaccine. Updated epidemiological information is available on WHO’s website at http://who.int/ influenza.

Reference: Weekly Epidemiological Record, 79: 91 (2004)

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 19 enero 2012